BioCentury
ARTICLE | Company News

Basilea, Asahi Kasei Pharma deal

September 19, 2016 7:00 AM UTC

Basilea granted Asahi exclusive rights in Japan to develop and commercialize isavuconazole. Basilea will receive CHF7 million ($7.2 million) up front and is eligible for up to CHF60 million ($61.6 mil...